Abstract
Metastases remain the leading cause of cancer-related mortality. The oligometastasis hypothesis postulates that a spectrum of metastatic spread exists and that some patients with a limited burden of metastases can be cured with ablative therapy. Over the past decade, substantial advances in systemic therapies have resulted in considerable improvements in the outcomes of patients with metastatic cancers, warranting re-examination of the oligometastatic paradigm and the role of local ablative therapies within the context of the improved therapeutic responses, shifting patterns of disease recurrence and possible synergy with systemic treatments. Herein, we reframe the oligometastatic phenotype as a dynamic state for which locally ablative, metastasis-directed therapy improves clinical outcomes, including by prolonging survival and increasing cure rates. Important risk factors defining the metastatic spectrum are highlighted that inform both staging and therapy. Finally, we synthesize the literature on combining local therapies with modern systemic treatments, identifying general themes to optimally integrate ablative therapies in this context.
Key points
-
Metastases remain the leading cause of cancer-associated mortality; however, the oligometastasis hypothesis postulates the existence of a spectrum of metastatic spread.
-
In the context of modern systemic therapies and improved cancer detection, the oligometastatic phenotype is framed as a dynamic state within which local ablative therapies improve clinical outcome, including prolonging survival and achieving cure.
-
The definition of the oligometastatic state should be expanded beyond the number or size of metastases, and incorporate clinical risk factors, tumour biology, host biology and novel biomarkers that intersect to define the metastatic spectrum.
-
Blood-based biomarkers (such as circulating tumour DNA) might help select patients across the metastatic spectrum for systemic therapy and/or local therapy.
-
As imaging modalities are improved and become more sensitive, it will become increasingly possible to detect and locally ablate all oligometastases (including those previously undetectable with less-sensitive imaging techniques), potentially facilitating the de-escalation of systemic therapy.
-
In patients who are unable to be cured with ablative metastasis-directed therapies, cytoreduction might still improve the efficacy of systemic therapies via several mechanisms, such as elimination of subclones poised to confer resistance; thus, the integration of local therapies with evolving systemic treatments could result in long-term survival.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559–1564 (2011).
Hellman, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8–10 (1995).
Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378–382 (2011).
Palma, D. A. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393, 2051–2058 (2019).
Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446–453 (2018).
Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6, 650–659 (2020).
Ruers, T. et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC intergroup phase II study (EORTC 40004). Ann. Oncol. 23, 2619–2626 (2012).
Gomez, D. R. et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 17, 1672–1682 (2016).
Gomez, D. R. et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J. Clin. Onol. 37, 1558–1565 (2019).
Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41–50 (2020).
James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).
Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).
Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925–1936 (2016).
Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638–3646 (2017).
Guckenberger, M. et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 21, e18–e28 (2020).
Lievens, Y. et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother. Oncol. 148, 157–166 (2020).
Nordlinger, B. et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 77, 1254–1262 (1996).
Iwatsuki, S. et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J. Am. Coll. Surg. 189, 291–299 (1999).
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F. & Blumgart, L. H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230, 309–318; discussion 318–321 (1999).
Tanvetyanon, T. et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J. Clin. Oncol. 26, 1142–1147 (2008).
Choong, P. F. M., Pritchard, D. J., Rock, M. G., Sim, F. H. & Frassica, F. J. Survival after pulmonary metastasectomy in soft tissue sarcoma: prognostic factors in 214 patients. Acta Orthop. Scand. 66, 561–568 (1995).
van Geel, A. N. et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 77, 675–682 (1996).
Chudgar, N. P. et al. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J. Thorac. Cardiovasc. Surg. 154, 319–330.e1 (2017).
Wagner, J. S., Adson, M. A., Van Heerden, J. A., Adson, M. H. & Ilstrup, D. M. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann. Surg. 199, 502–508 (1984).
Pogrebniak, H. W., Roth, J. A., Steinberg, S. M., Rosenberg, S. A. & Pass, H. I. Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma. Ann. Thorac. Surg. 52, 197–203 (1991).
Treasure, T., Moller, H., Fiorentino, F. & Utley, M. Editorial comment: forty years on: pulmonary metastasectomy for sarcoma. Eur. J. Cardiothorac. Surg. 43, 799–800 (2013).
Treasure, T. et al. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial. Trials 20, 718 (2019).
Salama, J. K. et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118, 2962–2970 (2012).
Nuyttens, J. J. et al. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int. J. Radiat. Oncol. Biol. Phys. 91, 337–343 (2015).
Rusthoven, K. E. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27, 1572–1578 (2009).
Rusthoven, K. E. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27, 1579–1584 (2009).
Wang, X. S. et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol. 13, 395–402 (2012).
Milano, M. T., Zhang, H., Metcalfe, S. K., Muhs, A. G. & Okunieff, P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res. Treat. 115, 601–608 (2009).
David, S. et al. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast 49, 55–62 (2020).
Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. 38, 2830–2838 (2020).
Harrow, S. et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET)–extended long-term outcomes. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2022.05.004 (2022).
Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial [abstract]. J. Clin. Oncol. 38 (Suppl. 6), 10 (2020).
Tang, C. et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 22, 1732–1739 (2021).
Ruers, T. et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J. Natl Cancer Inst. 109, djx015 (2017).
Iyengar, P. et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 4, e173501 (2018).
Wang, X.-S. et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djac015 (2022).
Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).
Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).
You, R. et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 6, 1345–1352 (2020).
Soran, A. et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann. Surg. Oncol. 25, 3141–3149 (2018).
Khan, S. A. et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108). J. Clin. Oncol. 40, 978–987 (2022).
Shah, S. et al. Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget 9, 4375–4384 (2018).
Wang, D. Y. et al. Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. Cancer Immunol. Res. 5, 357–362 (2017).
Mahmood, U. et al. Retrospective review of outcomes following radiotherapy for oligoprogressive disease on immune checkpoint blockade. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2022.05.008 (2022).
Chicas-Sett, R. et al. Combination of stereotactic ablative radiotherapy with anti-PD-1 in oligoprogressive non-small-cell lung cancer and melanoma: results of a prospective multicenter observational study. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2022.05.013 (2022).
Weiss, J. et al. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat. Res. Commun. 19, 100126 (2019).
Iyengar, P. et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J. Clin. Oncol. 32, 3824–3830 (2014).
Cheung, P. et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur. Urol. 80, 693–700 (2021).
Tsai, C. J. et al. Consolidative use of radiotherapy to block (CURB) oligoprogression–interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast. Int. J. Radiat. Oncol. Biol. Phys. 111, 1325–1326 (2021).
[No authors listed] Highly focused radiation may curb oligoprogression. Cancer Discov. 12, 8–9 (2022).
Foster, C. C., Pitroda, S. P. & Weichselbaum, R. R. Beyond palliation: the rationale for metastasis-directed therapy for metastatic non-small cell lung cancer. J. Thorac. Oncol. 14, 1510–1512 (2019).
Reuben, A. et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom. Med. 2, 10 (2017).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Chalkidou, A. et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 22, 98–106 (2021).
Olson, R. A. et al. Population based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: preliminary results of the SABR-5 trial [abstract]. Int. J. Radiat. Oncol. Biol. Phys. 111 (Suppl. 3), S4 (2021).
Chmura, S. et al. Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 phase 1 trial. JAMA Oncol. 7, 845–852 (2021).
Al-Hallaq, H. A. et al. Rationale of technical requirements for NRG-BR001: the first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract. Radiat. Oncol. 6, e291–e298 (2016).
Olson, R. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer 20, 380 (2020).
Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 19, 816 (2019).
Ashworth, A. B. et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin. Lung Cancer 15, 346–355 (2014).
Newman, S. et al. Long-term survival with 18-fluorodeoxyglucose positron emission tomography-directed therapy in non-small cell lung cancer with synchronous solitary brain metastasis. Clin. Oncol. 33, 163–171 (2021).
Pastorino, U. et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J. Thorac. Cardiovasc. Surg. 113, 37–49 (1997).
Tanadini-Lang, S. et al. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother. Oncol. 123, 182–188 (2017).
Lussier, Y. A. et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS ONE 7, e50141 (2012).
Rueda, O. M. et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567, 399–404 (2019).
Pitroda, S. P. et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat. Commun. 9, 1793 (2018).
Iacobuzio-Donahue, C. A. et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806–1813 (2009).
Deek, M. P. et al. The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur. Urol. 80, 632–640 (2021).
Sutera, P. et al. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-021-00484-4 (2022).
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594.e12 (2018).
Oshima, G. et al. DNA methylation controls metastasis-suppressive 14q32-encoded miRNAs. Cancer Res. 79, 650–662 (2019).
Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98–101 (1989).
Fidler, I. J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3, 453–458 (2003).
de Groot, A. E., Roy, S., Brown, J. S., Pienta, K. J. & Amend, S. R. Revisiting seed and soil: examining the primary tumor and cancer cell foraging in metastasis. Mol. Cancer Res. 15, 361–370 (2017).
Van den Eynde, M. et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. Cancer Cell 34, 1012–1026.e3 (2018).
Siva, S. et al. Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the Trans Tasman Radiation Oncology Group 13.01 phase 2 randomized clinical trial. JAMA Oncol. 7, 1476–1485 (2021).
Arina, A. et al. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat. Commun. 10, 3959 (2019).
Hou, Y. et al. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci. Transl. Med. 13, eabb0130 (2021).
Yang, K. et al. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J. Exp. Med. 218, e20201915 (2021).
Jani, A. B. et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet 397, 1895–1904 (2021).
Siva, S. et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur. Urol. 74, 455–462 (2018).
Glicksman, R. M. et al. Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis. Eur. Urol. 80, 374–382 (2021).
Loupakis, F. et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. JCO Precis. Oncol. https://doi.org/10.1200/PO.21.00101 (2021).
Xia, L. et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1). Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-3044 (2021).
Dhiman, A. et al. Phase II prospective, open-label randomized controlled trial comparing standard of care chemotherapy with and without sequential cytoreductive interventions for patients with oligometastatic foregut adenocarcinoma and undetectable circulating tumor deoxyribose nucleic acid (ctDNA) levels. Ann. Surg. Oncol. https://doi.org/10.1245/s10434-021-11249-7 (2022).
Hopkins, A. M., Kichenadasse, G., McKinnon, R. A., Rowland, A. & Sorich, M. J. Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. Semin. Oncol. 46, 380–384 (2019).
Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960–4967 (2018).
Castello, A., Rossi, S., Mazziotti, E., Toschi, L. & Lopci, E. Hyperprogressive disease in patients with non–small cell lung cancer treated with checkpoint inhibitors: the role of 18F-FDG PET/CT. J. Nucl. Med. 61, 821–826 (2020).
Chardin, D. et al. Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J. Immunother. Cancer 8, e000645 (2020).
Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363–376.e13 (2020).
Marsavela, G. et al. Circulating tumor DNA predicts outcome from first-, but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy. Clin. Cancer Res. 26, 5926–5933 (2020).
Dall’Olio, F. G. et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 19, 75–90 (2022).
Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).
Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y.-X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017).
Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).
Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845–1851 (2018).
Bauml, J. M. et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol. 5, 1283–1290 (2019).
Siva, S. et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma–the RAPPORT trial. Eur. Urol. 81, 364–372 (2022).
Bestvina, C. M. et al. A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J. Thorac. Oncol. 17, 130–140 (2022).
Luke, J. J. et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J. Clin. Oncol. 36, 1611–1618 (2018).
Luke, J. J. et al. Improved survival associated with local tumor response following multisite radiotherapy and pembrolizumab: secondary analysis of a phase I trial. Clin. Cancer Res. 26, 6437–6444 (2020).
Foster, C. C. et al. Phase I study of stereotactic body radiotherapy plus nivolumab and urelumab or cabiralizumab in advanced solid tumors. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-0810 (2021).
Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728–734 (2005).
Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379–5388 (2009).
McBride, S. et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J. Clin. Oncol. 39, 30–37 (2021).
Masini, C. et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study. Eur. Urol. https://doi.org/10.1016/j.eururo.2021.09.016 (2021).
Mahmood, U. et al. A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 109, 134–144 (2021).
Welsh, J. et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J. Immunother. Cancer 8, e001001 (2020).
Theelen, W. S. M. E. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5, 1276–1282 (2019).
Theelen, W. S. M. E. et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9, 467–475 (2021).
Tian, S. et al. Lung stereotactic body radiation therapy and concurrent immunotherapy: a multicenter safety and toxicity analysis. Int. J. Radiat. Oncol. Biol. Phys. 108, 304–313 (2020).
Tchelebi, L. T. et al. Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies. JNCI Cancer Spectr. 5, pkab050 (2021).
Jia, W. et al. An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib. Radiother. Oncol. 152, 96–100 (2020).
Corkum, M. T., Fakir, H., Palma, D. A., Nguyen, T. & Bauman, G. S. Can polymetastatic disease be ARRESTed using SABR? A dosimetric feasibility study to inform development of a phase 1 trial. Adv. Radiat. Oncol. 6, 100734 (2021).
Guckenberger, M. et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother. Oncol. 118, 485–491 (2016).
Young, E. R., Diakos, E., Khalid-Raja, M. & Mehanna, H. Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis. Clin. Otolaryngol. 40, 208–218 (2015).
Al-Batran, S.-E. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 3, 1237–1244 (2017).
Tachezy, M. et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery 160, 136–144 (2016).
Kuo, S.-W. et al. Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma. Ann. Surg. Oncol. 14, 992–997 (2007).
Franzese, C. et al. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J. Cancer Res. Clin. Oncol. 146, 2289–2297 (2020).
Scorsetti, M. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J. Cancer Res. Clin. Oncol. 141, 543–553 (2015).
Kavolius, J. P. et al. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16, 2261–2266 (1998).
Patel, V. et al. Survival after metastasectomy for metastatic urothelial carcinoma: a systematic review and meta-analysis. Bladder Cancer 3, 121–132 (2017).
Otto, T., Krege, S., Suhr, J. & Rübben, H. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 57, 55–59 (2001).
Anraku, M. et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J. Thorac. Cardiovasc. Surg. 127, 1107–1112 (2004).
Lazzari, R. et al. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int. J. Radiat. Oncol. Biol. Phys. 101, 650–660 (2018).
Trovo, M. et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother. Oncol. 126, 177–180 (2018).
Sosman, J. A. et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group clinical trial S9430. Cancer 117, 4740-06 (2011).
Howard, J. H. et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I). Ann. Surg. Oncol. 19, 2547–2555 (2012).
Acknowledgements
The work of the authors is supported by the Virginia and D. K. Ludwig Fund for Cancer Research and the Foglia Family Foundation.
Author information
Authors and Affiliations
Contributions
All authors made substantial contributions to all aspects of the preparation of this manuscript.
Corresponding author
Ethics declarations
Competing interests
S.P.P and R.R.W. are co-inventors on a patent entitled “Methods and kits for diagnosis and triage of patients with colorectal liver metastases” and on a provisional patent entitled “Molecular subtyping of colorectal liver metastases to personalize treatment approaches”. A.J. has served in a consulting role for Isoray. S.J.C. has participated on advisory boards for AstraZeneca and Genentech, receives research support from AstraZeneca, Bristol Myers Squibb, EMD Serono and Merck, and his spouse is employed as the medical director of Astellas Pharma. R.R.W. has stock and other ownership interests in Aqualung Therapeutics, Boost Therapeutics, Coordination Pharmaceuticals, Immvira LLC, Magi Therapeutics, Oncosenescence and Reflexion Pharmaceuticals; has served in a consulting or advisory role for Aettis, Aqualung Therapeutics, AstraZeneca, Coordination Pharmaceuticals, Genus, Highlight Therapeutics, Merck Serono, Nano Proteagen, NKMax America and Shuttle Pharmaceuticals; has received research grants from Regeneron and Varian; and has received compensation including travel, accommodation or expense reimbursement from AstraZeneca, Boehringer Ingelheim and Merck Serono.
Peer review
Reviewer information
Nature Reviews Clinical Oncology thanks A. Louie, who co-reviewed with R.J.M. Correa; M. Guckenberger; S. Siva; and other, anonymous, reviewer(s), for their contribution to the peer review of this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Katipally, R.R., Pitroda, S.P., Juloori, A. et al. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol 19, 585–599 (2022). https://doi.org/10.1038/s41571-022-00655-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00655-9
This article is cited by
-
Emerging evidence and treatment paradigm of non-small cell lung cancer
Journal of Hematology & Oncology (2023)
-
Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectiveness
Clinical and Translational Oncology (2023)
-
Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution
Breast Cancer Research and Treatment (2023)
-
CACA guidelines for holistic integrative management of nasopharyngeal carcinoma
Holistic Integrative Oncology (2023)
-
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
World Journal of Urology (2022)